In last trading session, Ocular Therapeutix Inc (NASDAQ:OCUL) saw 2.04 million shares changing hands with its beta currently measuring 1.47. Company’s recent per share price level of $7.90 trading at $0.05 or 0.64% at ring of the bell on the day assigns it a market valuation of $1.26B. That closing price of OCUL’s stock is at a discount of -48.99% from its 52-week high price of $11.77 and is indicating a premium of 48.61% from its 52-week low price of $4.06. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.54 million shares which gives us an average trading volume of 1.48 million if we extend that period to 3-months.

For Ocular Therapeutix Inc (OCUL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.08. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.28 in the current quarter.

Ocular Therapeutix Inc (NASDAQ:OCUL) trade information

Upright in the green during last session for gaining 0.64%, in the last five days OCUL remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $7.90 price level, adding 4.01% to its value on the day. Ocular Therapeutix Inc’s shares saw a change of -7.49% in year-to-date performance and have moved 10.18% in past 5-day. Ocular Therapeutix Inc (NASDAQ:OCUL) showed a performance of 4.91% in past 30-days. Number of shares sold short was 12.59 million shares which calculate 6.87 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 19 to the stock, which implies a rise of 58.42% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 19. It follows that stock’s current price would drop -140.51% in reaching the projected high whereas dropping to the targeted low would mean a loss of -140.51% for stock’s current value.

Ocular Therapeutix Inc (OCUL) estimates and forecasts

This year revenue growth is estimated to rise 11.16% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 16.95M for the same. And 11 analysts are in estimates of company making revenue of 17.7M in the next quarter. Company posted 14.77M and 16.44M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.51% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 0.62% while estimates for its earnings growth in next 5 years are of 4.84%.

Ocular Therapeutix Inc (NASDAQ:OCUL)’s Major holders

Insiders are in possession of 1.01% of company’s total shares while institution are holding 85.71 percent of that, with stock having share float percentage of 86.58%. Investors also watch the number of corporate investors in a company very closely, which is 85.71% institutions for Ocular Therapeutix Inc that are currently holding shares of the company. SUMMER ROAD LLC is the top institutional holder at OCUL for having 14.89 million shares of worth $101.82 million. And as of 2024-06-30, it was holding 8.9767 of the company’s outstanding shares.

The second largest institutional holder is VR ADVISER, LLC, which was holding about 12.76 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.6964 of outstanding shares, having a total worth of $87.3 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 4.64 shares of worth $36.68 million or 2.92% of the total outstanding shares. The later fund manager was in possession of 4.16 shares on Mar 31, 2025 , making its stake of worth around $32.88 million in the company or a holder of 2.62% of company’s stock.